+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Estrogen receptor-positive and estrogen receptor-negative human breast cancer cells: Regulation of expression of cancer-related genes by estradiol and tamoxifen



Estrogen receptor-positive and estrogen receptor-negative human breast cancer cells: Regulation of expression of cancer-related genes by estradiol and tamoxifen



Current Signal Transduction Therapy 3(1): 7-21




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 020986314

Download citation: RISBibTeXText

DOI: 10.2174/157436208783334286


Related references

Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines. Breast Cancer 9: 537-550, 2017

Estrogen Induces Estrogen-related Receptor a Gene Expression and Chromatin Structural Changes in Estrogen Receptor (ER)-positive and ER-negative Breast Cancer Cells. The Journal of Biological Chemistry 283(11): 52-63, 2008

Estrogen induces estrogen-related receptor alpha gene expression and chromatin structural changes in estrogen receptor (ER)-positive and ER-negative breast cancer cells. Journal of Biological Chemistry 283(11): 6752-6763, 2008

Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen. Endocrinology 144(5): 1812-1824, 2003

Efficacy of UFT plus Tamoxifen for Estrogen-Receptor-Positive Breast Cancer and Tamoxifen plus UFT for Estrogen-Receptor-Negative Breast Cancer : Adjuvant Therapy after Administration of Mitomycin. Clinical Drug Investigation 23(11): 689-699, 2003

Changes in estrogen receptor function in a tamoxifen resistant and ICI 164,384 and ICI 182,780 sensitive estrogen receptor positive human breast cancer cell line derived from MCF-7 cells. Journal of Cellular Biochemistry Suppl. 0(18B): 354, 1994

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. Journal of the National Cancer Institute 97(17): 1254-1261, 2005

Dna synthesis in estrogen receptor positive er positive human breast cancer takes place preferentially in estrogen receptor negative er negative cells. Proceedings of the American Association for Cancer Research Annual Meeting 30: 292, 1989

DNA synthesis in estrogen receptor-positive human breast cancer takes place preferentially in estrogen receptor-negative cells. Cancer 64(4): 842-848, 1989

A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Molecular Biology Reports 35(1): 23-27, 2008

Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC). Annals of Oncology 24(8): 1986-1993, 2013

Characterization and quantitation of anti estrogen binding sites in estrogen receptor positive and estrogen receptor negative human breast cancer cell lines. Cancer Research 43(7): 3094-3100, 1983

Quercetin induces type-II estrogen-binding sites in estrogen-receptor-negative (MDA-MB231) and estrogen-receptor-positive (MCF-7) human breast-cancer cell lines. International Journal of Cancer 54(3): 462-466, 1993

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. Journal of Clinical Oncology 29(31): 4160-4167, 2011

Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. Journal of Clinical Oncology 23(16_Suppl): 510-510, 2016